Jan 09 2021 23 mins 1
Question: If NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening? This conversation asks a two-part question: How do we motivate primary care treaters and specialists who treat metabolic syndromes to manage NAFLD more aggressively? The conversation considers education and telemedicine in this context and then turns to two very ambitious concepts. One of these deals with screening, the other with treatment before approvals. Listen until the end then let us know what you think and what big ideas you, yourself might have.
